‘Time to Trust the Long-Term?' Analysts Maintain Buy on UnitedHealth Stock (UNH) Despite Price Target Cuts
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Nevertheless, both analysts maintain a Buy rating on UNH stock, citing confidence in long-term prospects.
Truist Lowers Target but Sees Stability Ahead
MacDonald lowered his price target on UnitedHealth to $345 from $360. The analyst expects Q2 results to show a mixed picture across the Healthcare sector, with some companies doing better than others depending on how they manage patient usage and costs.
Despite these short-term pressures, he is optimistic about the long-term outlook due to strong demand for healthcare services. Also, the Reconciliation Bill has made the rules and regulations clearer, which could help stabilize the company's business going forward.
Leerink Cuts Target but Projects Recovery by 2027
Leerink Partners' Mayo lowered the price target from $355 to $340, citing fading investor expectations as people wait for the company to update its 2025 financial guidance. He believes earnings in the $18–$19 per share range could ease concerns about shrinking margins.
On the positive side, the analyst sees this as the start of a long-term recovery. He expects profit margins to improve gradually over the next few years, with stronger growth likely starting in 2027, once the company finishes switching out of its current Medicare risk model.
Is UNH a Good Buy Right Now?
Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, seven Holds, and one Sell assigned in the last three months. At $357.14, the average UnitedHealth stock price target implies a 21.75% upside potential.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
‘A House Is Not An Investment': Billionaire Real Estate Investor Grant Cardone Warns to Stop Buying Houses
Grant Cardone, a prominent real estate investor and financial educator, is known for upending conventional wisdom in personal finance circles. One such recent assertion on Cardone's social media — specifically, 'A HOUSE IS NOT AN INVESTMENT! You have to feed it monthly, mortgage, property taxes, insurance and maintenance.' — directly targets conventional wisdom about the value of owning a primary residence. Shop Top Mortgage Rates A quicker path to financial freedom Personalized rates in minutes Your Path to Homeownership Cardone's statement stands out in a culture where purchasing a home is frequently viewed as a primary financial goal and a key pathway to building wealth. For generations, the promise of equity creation and eventual asset appreciation has underpinned the 'American dream' of homeownership. However, in his X early July post, Cardone draws attention to the recurring, unavoidable expenses that come with owning a home — which include monthly mortgage payments, property taxes, insurance premiums, and ongoing maintenance. His view is that rather than generating income, these expenditures often consume resources that could otherwise be deployed in assets with better return profiles. More News from Barchart With UnitedHealth Under DOJ Investigation, Should You Buy, Sell, or Hold UNH Stock Now? Trump Won't Take Away Tesla's Subsidies. Does That Make TSLA Stock a Safe Buy Here? Can AMD Stock Hit $210 in 2025? Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Authority Rooted in Real Estate Expertise Cardone's authority on the subject is founded in decades of hands-on experience. As the founder and CEO of Cardone Capital, he oversees a multibillion-dollar portfolio of multifamily properties and commercial assets. Unlike many who champion homeownership as an investment, Cardone advocates for those with the means and wherewithal to purchase income-producing real estate, such as apartment buildings and commercial properties, over single-family homes intended for personal use. His own personal and professional history lends a certain credibility to Cardone's contrarian take. After rising from modest beginnings, Cardone built his fortune through aggressive investment strategies, favoring scalable assets with consistent cash flow over traditional routes like homeownership. He has authored several bestselling books on real estate investing, delivered seminars worldwide, and amassed a large following through his advocacy for financial discipline and entrepreneurship. Why the Perspective Resonates Cardone's viewpoint reflects ongoing debates in financial circles about the costs versus benefits of homeownership. Aside from the substantial upfront and recurring expenses, the liquidity and opportunity costs associated with owning a home are significant. Unlike rental properties, a primary residence does not generate passive income, and periods of slow or stagnant price growth can further diminish a home's investment appeal. Financial advisors have long pointed out that maintenance, taxes, and unpredictable market swings can sometimes leave homeowners with lower-than-expected or even negative returns. The outspoken investor's position also tracks with broader shifts in the post-crisis housing and investment markets over the past decade. As interest rates remain elevated and housing affordability challenges persist, younger generations are increasingly reconsidering whether buying a home is a prudent step toward wealth. In the current landscape, Cardone's critique finds a very receptive audience among those weighing non-traditional paths to financial security. How Rates Change the Homeownership Story The ongoing dialogue around homeownership has become particularly relevant amid today's unique economic circumstances. With mortgage rates and property taxes rising in many regions, the monthly carrying costs for homeowners have increased, even as housing prices remain elevated. These trends support Cardone's caution — and his message emphasizes that buyers should scrutinize the financial realities of ownership rather than assume it is a guaranteed investment. On balance, Grant Cardone's statement encapsulates a core message of his broader philosophy: namely, that financial security and growth can be achieved by deploying capital in assets that generate income, control costs, and offer scalable opportunities. By questioning the investment value of homeownership, he invites individuals to critically evaluate the true ROI of their largest personal expenditures and to consider alternative, potentially more lucrative avenues to financial independence. On the date of publication, Caleb Naysmith did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Gizmodo
37 minutes ago
- Gizmodo
Feds Launch Experiment to Have Medicare Cover GLP-1 Weight Loss Drugs
The federal government may not have closed the window on paying for GLP-1 weight loss drugs like Ozempic and Zepbound after all. The Trump administration is reportedly planning to conduct an experiment that will allow some people to have obesity drugs covered by their Medicaid and Medicare plans. The Washington Post first broke the news Friday morning, having reportedly obtained documents from the Centers for Medicare and Medicaid Services outlining the plan. It would enable state Medicaid programs and Medicare Part D insurance plans to cover people's medications explicitly meant for 'weight management,' starting next year. Should the experiment go well, it could pave the way to widespread Medicare and Medicaid coverage of these expensive but effective drugs. A Staggering Number of U.S. Adults Are Eligible for Ozempic, Study Finds As things stand now, Medicare cannot directly cover any medications for treating obesity, including newer GLP-1 agents like semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). Programs do have some leeway in providing coverage to people taking Ozempic and similar drugs for diabetes or certain obesity-related conditions, such as heart disease. Last year, the Biden administration proposed a rule designed to end this restriction, opening up coverage to some 7 million Americans on Medicare and Medicaid by 2026. In April this year, though, the Trump administration dropped the proposed rule entirely. However, Health Secretary Robert F. Kennedy Jr., who's previously criticized Ozempic in the past, did state at the time that the White House was still considering a 'framework' to expand coverage. Trump Is Promising to Lower Drug Prices. Don't Count on It According to the Washington Post, the Center for Medicare and Medicaid Innovation—an organization tasked with finding ways to lower health care costs and improve patient care—will be in charge of the experiment. Some specifics of the plan, including the exact criteria for eligibility, may still be up in the air, since the government could provide a window for public comment and further modification if it so chooses. As currently outlined, though, the experiment is expected to run for at least five years. Medicaid programs would reportedly be able to offer coverage starting in April 2026, while Medicare plans could do so in January 2027. The newest GLP-1 drugs like semaglutide have proven to be much more effective at helping people lose weight than diet and exercise alone. But their high costs and limited insurance coverage have impeded many people from obtaining or staying on these treatments long-term (some users are also unable to tolerate the common gastrointestinal side effects they cause). That said, this proposed plan is the latest sign that these cost issues are improving. The list prices of Ozempic and similar drugs have started to drop as of late; for instance, America's upstairs neighbor Canada is expected to approve the first generics of Ozempic early next year (that probably won't happen until 2030 in the U.S., though). The likely arrival of new approved competitors to these drugs as early as next year is also expected to drive down prices in general.
Yahoo
an hour ago
- Yahoo
An Unpopular Pick: 5 Reasons Why Buying UnitedHealth Group Stock Now Could Be a Brilliant Move
Key Points UnitedHealth Group continues to face multiple challenges. The company has a plan to address the issues and boost its bottom line. The stock is a bargain with solid long-term growth prospects. 10 stocks we like better than UnitedHealth Group › An old country song morbidly titled "Gloom, Despair, and Agony on Me" included the lyrics, "If it weren't for bad luck, I'd have no luck at all." This might be an apt motto for UnitedHealth Group (NYSE: UNH) these days. The healthcare giant continued to disappoint investors with its 2025 second-quarter update, revealing that full-year earnings will be worse than expected. The U.S. Department of Justice (DOJ) is conducting an investigation of UnitedHealth related to its Medicare billing practices, and its share price has plunged nearly 60% from the peak set in late 2024. UnitedHealth Group stock is a decidedly unpopular pick. However, here are five reasons why buying this beaten-down stock could be a brilliant move. 1. The company has a plan to address its problems It would be one thing if UnitedHealth Group's challenges were insurmountable, but they're not. The company has a clear and compelling plan to address its problems. UnitedHealth didn't anticipate how hard it would be hit by rising medical costs, especially with its Medicare Advantage plans. The most effective solution to this issue is simple: Raise premiums. That's exactly what UnitedHealth plans to do, but it has to wait until the beginning of next year for most premium hikes to take effect. Since commercial plans renew throughout the year, the company can implement premium changes more quickly with this line of business. Tim Noel, the new CEO of the UnitedHealthcare insurance business, said in the Q2 earnings call that his unit will have "strongly responsive pricing for 2026." That's not the only step the company is taking, though. Noel stated that UnitedHealthcare has "stepped up our audit clinical policy and payment integrity tools to protect customers and patients from unnecessary costs." He added that the business is also streamlining its provider networks, especially for Medicare Advantage plans. UnitedHealth Group's Optum segment isn't performing as well as desired, either. Again, though, the company is implementing a plan to fix the problems. Optum CEO Patrick Conway said in the Q2 call that price increases are coming to reflect high patient acuity and risk. He also mentioned that Optum Health will discontinue serving around 200,000 patients. 2. Cost-cutting should boost the bottom line UnitedHealth Group is also moving forward with cost-cutting initiatives to boost its bottom line. CEO Stephen Hemsley referred to "meaningful cost opportunities within the enterprise" in his comments during the Q2 call, adding, "[W]e are pursuing them with urgency." Noel highlighted his unit's efforts to scale artificial intelligence (AI) across health plan operations, which should generate cost savings while improving patient and provider experiences. Conway expects Optum Health to deliver nearly $1 billion in cost savings in 2026. 3. Long-term growth prospects remain strong Despite UnitedHealth's challenges over the near term, its long-term growth prospects remain strong. The company expects to return to earnings growth next year. Hemsley predicts that earnings growth will accelerate in 2027 and beyond. Is this upbeat assessment merely the result of a CEO looking through rose-colored glasses? I don't think so. The consensus among analysts surveyed by LSEG is that UnitedHealth Group will deliver solid year-over-year earnings growth in 2026. 4. An experienced, steady hand is now at the wheel It's also important for investors to remember that UnitedHealth Group once again has an experienced, steady hand at the wheel. Hemsley returned to run the company two months ago. He previously served as CEO from 2006 to 2017, a period during which UnitedHealth Group flourished and its share price soared. 5. The stock is a bargain Last, but not least, UnitedHealth Group stock is a bargain. Its shares trade at a forward price-to-earnings ratio of below 11.6. That's not much higher than the valuation during the financial crisis of 2008 and 2009. Does the DOJ investigation justify such a low earnings multiple? I don't think so. UnitedHealth survived a previous lengthy investigation, with a court-appointed Special Master ultimately concluding that there wasn't evidence that the company had done anything wrong. Independent audits from the Centers for Medicare and Medicaid Services show that UnitedHealth's Medicare practices are, in the company's words, "among the most accurate in the industry." UnitedHealth Group insists that it "has full confidence in its practices." Should you buy stock in UnitedHealth Group right now? Before you buy stock in UnitedHealth Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $630,291!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,791!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy. An Unpopular Pick: 5 Reasons Why Buying UnitedHealth Group Stock Now Could Be a Brilliant Move was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
